BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.
BLU-945 是一种强效且选择性的下一代 EGFR TKI,在奥希替尼耐药的非小细胞肺癌模型中具有抗肿瘤活性
期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/17588359241280689
Lim Sun Min, Schalm Stefanie S, Lee Eun Ji, Park Sewon, Conti Chiara, Millet Yves A, Woessner Rich, Zhang Zhuo, Tavera-Mendoza Luz E, Stevison Faith, Albayya Faris, Dineen Thomas A, Hsieh John, Oh Seung Yeon, Zalutskaya Alena, Rotow Julia, Goto Koichi, Lee Dae-Ho, Yun Mi Ran, Cho Byoung Chul